Short communication: Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures;Kisa bi̇ldi̇ri̇: Hastane enfeksi̇yonu etkeni̇ olarak kan kültürleri̇nden i̇zole edi̇len Escherichia coli ve Klebsiella spp. suşlarinda geni̇şlemi̇ş spektrumlu beta-laktamaz prevalansi

Mikrobiyoloji Bulteni

Volumn 41, Issue 4, 2007, Pages 579-584

  Zarakolu, Pinar ^a   Metan, Gökhan ^b   Hasçelik, Gülsen ^a   Akova, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Escherichia coli; Extended spectrum beta lactamase; Klebsiella oxytoca; Klebsiella pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; ENZYME INHIBITOR;

ARTICLE; BACTEREMIA; CROSS INFECTION; DRUG COMBINATION; DRUG EFFECT; ENTEROBACTER INFECTION; ENZYMOLOGY; ESCHERICHIA COLI; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PREVALENCE; TURKEY (REPUBLIC);

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; CROSS INFECTION; DRUG COMBINATIONS; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; TURKEY;

EID: 48849096927     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 218: 657-86.
2. Blomberg B, Jureen R, Manji KP, et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 2005; 43: 745-9.
3. Cormican MG, Marshall SA, Jones RN. Detection of extended-spectrum β-lactamases producing strains by the Etest ESBL screen. J Clin Microbiol 1996; 34:1880-4.
4. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi, S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-17.
5. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32:1085-9.
6. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
7. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-91.
8. Lautenbach E, Patel BL, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71.
9. Anonymous. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23: 106-8.
10. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patients outcomes in the ICU setting. Chest 2000; 118: 146-55.
11. Stobberingh EE, Arends J, HoogkAmb-Korstanje JAA, et al. Occurrence of extended-spectrum beta-lactamases in Dutch hospitals. Infection 1999; 27: 348-54.
12. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281: 67-71.
13. Du B, Long Y, Liu H, et al. Extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28:1718-23.
14. Gunseren F, Mamikoglu L, Ozturk S, et al. A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 1999; 43: 373-8.
15. Ozgunes I, Erben N, Kiremitci A, et al. The prevalence of extended-spectrum beta lactamase producing E.coli and Klebsiella pneumoniae in clinical isolates and risk factors. Saudi Med J 2006; 27: 608-12.
16. Alici O, Açikgöz ZC, Göçer S, Gambarzade S, Karahocagil MK. Prevalence of extended-spectrum beta lactamases in gram negative rods: data of 2001-2004 period. Mikrobiyol Bul 2006; 40: 355-61.
17. Eksi F, Ozer G, Balci I. Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp. Mikrobiyol Bul 2007; 41: 447-52.
18. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
19. Labia R. Analysis of the bla(toho) gene coding for Toho-2 beta-lactamase. Antimicrob Agents Chemother 1999; 43: 2576-7.
20. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-9.
21. Steward CD, Rasheed JK, Hubert SK, et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol 2001; 39: 2864-72.
22. Coudron PE, Moland ES, Sanders CC. Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol 1997; 35: 2593-7.
23. Unal S, Masterton R, Goossens H. Bacteraemia in Europe antimicrobial susceptibility data from the MYSTIC surveillance programme. Int J Antimicrob Agents 2004; 23: 155-63.
24. Gür D, Gülay Z, Arikan Akan Ö ve ark. Gram negatif hastane izolatlarinda yeni beta-laktamlara direnç ve GSBL sikliǧi. Çok merkezli HİTİT çalişmasi sonuçlari. 12. Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastaliklari Kongresi, 16-20 Kasim 2005. Antalya. Kongre Kitabi, s: 212.
25. Metan G, Zarakolu P, Çakir B, Hasçelik G, Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2005; 26: 254-7.